Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Donafenib and Camrelizumab in the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Retrospective, Single-Arm Study
For patients with uHCC, the combination therapy of FOLFOX-HAIC with donafenib and camrelizumab demonstrates favorable efficacy and manageable adverse events.
Authors
- Yin Zhou (ORCID: https://orcid.org/0000-0002-8297-8621)
- Ruirui Sun (ORCID: https://orcid.org/0009-0004-5495-6347)
- Yaowu Zhao (ORCID: https://orcid.org/0000-0002-6872-9119)
- Ping Huang (ORCID: https://orcid.org/0000-0003-1775-029X)
- Yu-hao Qiu
- Jiachu Li
- Long Pan
- Chenrui Wu (ORCID: https://orcid.org/0000-0002-4933-6918)
- Yang Gou
- Zhouyan Wang
- Zixuan Fu
Institutions
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Journal of Hepatocellular Carcinoma
- Published
- 2025-07-01
- DOI
- https://doi.org/10.2147/jhc.s525454
- Citations
- 2
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 2.64
Funders
- Chongqing Medical University